Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1957 1
1958 4
1959 4
1960 1
1961 1
1962 2
1963 5
1964 4
1965 1
1966 1
1967 4
1969 3
1970 4
1971 1
1974 2
1975 2
1976 1
1978 1
1979 2
1980 1
1981 2
1982 2
1983 2
1988 2
1991 2
1993 1
1997 1
2000 3
2001 1
2003 1
2004 1
2005 1
2006 5
2007 4
2008 4
2009 2
2010 8
2011 8
2012 8
2013 8
2014 15
2015 11
2016 14
2017 8
2018 10
2019 15
2020 19
2021 22
2022 22
2023 18
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

242 results

Results by year

Filters applied: . Clear all
Page 1
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, O'Brien S, Yenerel MN, Illés A, Kay N, Garcia-Marco JA, Mato A, Pinilla-Ibarz J, Seymour JF, Lepretre S, Stilgenbauer S, Robak T, Rothbaum W, Izumi R, Hamdy A, Patel P, Higgins K, Sohoni S, Jurczak W. Byrd JC, et al. Among authors: hamdy a. J Clin Oncol. 2021 Nov 1;39(31):3441-3452. doi: 10.1200/JCO.21.01210. Epub 2021 Jul 26. J Clin Oncol. 2021. PMID: 34310172 Free PMC article. Clinical Trial.
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn J, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Covey T, Dua R, Hamdy A, Huang X, Izumi R, Patel P, Rothbaum W, Slatter JG, Jurczak W. Wang M, et al. Among authors: hamdy a. Lancet. 2018 Feb 17;391(10121):659-667. doi: 10.1016/S0140-6736(17)33108-2. Epub 2017 Dec 11. Lancet. 2018. PMID: 29241979 Free PMC article. Clinical Trial.
Acalabrutinib in treatment-naive chronic lymphocytic leukemia.
Byrd JC, Woyach JA, Furman RR, Martin P, O'Brien S, Brown JR, Stephens DM, Barrientos JC, Devereux S, Hillmen P, Pagel JM, Hamdy A, Izumi R, Patel P, Wang MH, Jain N, Wierda WG. Byrd JC, et al. Among authors: hamdy a. Blood. 2021 Jun 17;137(24):3327-3338. doi: 10.1182/blood.2020009617. Blood. 2021. PMID: 33786588 Free PMC article. Clinical Trial.
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR. Byrd JC, et al. Among authors: hamdy a. N Engl J Med. 2016 Jan 28;374(4):323-32. doi: 10.1056/NEJMoa1509981. Epub 2015 Dec 7. N Engl J Med. 2016. PMID: 26641137 Free PMC article. Clinical Trial.
A multinational Delphi consensus to end the COVID-19 public health threat.
Lazarus JV, Romero D, Kopka CJ, Karim SA, Abu-Raddad LJ, Almeida G, Baptista-Leite R, Barocas JA, Barreto ML, Bar-Yam Y, Bassat Q, Batista C, Bazilian M, Chiou ST, Del Rio C, Dore GJ, Gao GF, Gostin LO, Hellard M, Jimenez JL, Kang G, Lee N, Matičič M, McKee M, Nsanzimana S, Oliu-Barton M, Pradelski B, Pyzik O, Rabin K, Raina S, Rashid SF, Rathe M, Saenz R, Singh S, Trock-Hempler M, Villapol S, Yap P, Binagwaho A, Kamarulzaman A, El-Mohandes A; COVID-19 Consensus Statement Panel. Lazarus JV, et al. Nature. 2022 Nov;611(7935):332-345. doi: 10.1038/s41586-022-05398-2. Epub 2022 Nov 3. Nature. 2022. PMID: 36329272 Free PMC article.
Superantigens and SARS-CoV-2.
Hamdy A, Leonardi A. Hamdy A, et al. Pathogens. 2022 Mar 23;11(4):390. doi: 10.3390/pathogens11040390. Pathogens. 2022. PMID: 35456065 Free PMC article.
The World Health Network: a global citizens' initiative.
Bar-Yam Y, Gurdasani D, Baker MG, Scally G, George S, Kvalsvig A, Fhaoláin SN, Chiou ST, Drury J, Duckett S, Ding EL, Gershenson C, Gibson C, Greenhalgh T, Hamdy A, Hyde Z, James T, Jimenez JL, McKee M, Michie S, Pagel C, Philippe C, Prather K, Raina SK, Ricciardi W, Rubin M, Ryan T, Schneider MF, Staines A, West R, Ziauddeen H. Bar-Yam Y, et al. Among authors: hamdy a. Lancet. 2021 Oct 30;398(10311):1567-1568. doi: 10.1016/S0140-6736(21)02246-7. Epub 2021 Oct 28. Lancet. 2021. PMID: 34755625 Free PMC article. No abstract available.
VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia.
Sher S, Whipp E, Walker J, Zhang P, Beaver L, Williams K, Orwick S, Ravikrishnan J, Walker B, Perry E, Gregory C, Purcell M, Pan A, Yan P, Alinari L, Johnson AJ, Frigault MM, Greer JM, Hamdy A, Izumi R, Mo X, Sampath D, Woyach J, Blachly J, Byrd JC, Lapalombella R. Sher S, et al. Among authors: hamdy a. Leukemia. 2023 Feb;37(2):326-338. doi: 10.1038/s41375-022-01758-z. Epub 2022 Nov 14. Leukemia. 2023. PMID: 36376377 Free PMC article.
242 results